Literature DB >> 31997551

Rate of kidney function decline and factors predicting progression of kidney disease in type 2 diabetes mellitus patients with reduced kidney function: A nationwide retrospective cohort study.

Wisit Kaewput1, Charat Thongprayoon2, Api Chewcharat2, Ram Rangsin1, Bancha Satirapoj3, Chalermrat Kaewput4, Picha Suwannahitatorn5, Tarun Bathini6, Michael A Mao7, Liam D Cato8, Andrew M Harrison9, Pradeep Vaitla10, Wisit Cheungpasitporn10.   

Abstract

Currently, the data on independent risk factors for the progression of kidney disease in type 2 diabetes mellitus (T2DM) patients with CKD are limited. This study aimed to investigate CKD progression in T2DM patients who have reduced kidney function with baseline estimated glomerular filtration rate (eGFRs) between 15 and 59 mL/min/1.73 m2 . This study was composed of a nationwide retrospective cohort of adult T2DM patients from 831 public hospitals in Thailand during the year 2015. T2DM patients with CKD stages 3 and 4 were followed up, until development of CKD stage 5, requirement of chronic dialysis, loss to follow-up, death, or 31 May 2018, whichever came first. Cox proportional hazard regression was utilized for analysis. A total of 8464 participants were included; 30.4% were male. The mean age was 69 ± 10 years. The mean eGFR was 45 ± 11 mL/min/1.73 m2 . The incidence of CKD stage 5 or the need for chronic dialysis was 16.4 per 1000 person-years. The annual rate of eGFR decline during a mean follow-up of 29 months was -2.3 mL/min/1.73 m2 ; 14.4% had a rapid decline in eGFR. The risk factors associated with progression to CKD stage 5 or the need for chronic dialysis were diabetes duration, systolic blood pressure, serum uric acid, albuminuria, and baseline eGFR. Conversely, older age and the use of renin-angiotensin aldosterone system blockade were associated with decreased risks for rapid CKD progression and incidence CKD stage 5 or dialysis. This study identifies multiple predictive risk factors that support a multifaceted approach to prevent progression of advanced CKD.
© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  albuminuria; chronic kidney disease; end-stage kidney disease; glomerular filtration rate; type 2 diabetes mellitus

Year:  2020        PMID: 31997551     DOI: 10.1111/1744-9987.13480

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  3 in total

1.  Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline.

Authors:  Mathias Gorski; Bettina Jung; Yong Li; Pamela R Matias-Garcia; Matthias Wuttke; Stefan Coassin; Chris H L Thio; Marcus E Kleber; Thomas W Winkler; Veronika Wanner; Jin-Fang Chai; Audrey Y Chu; Massimiliano Cocca; Mary F Feitosa; Sahar Ghasemi; Anselm Hoppmann; Katrin Horn; Man Li; Teresa Nutile; Markus Scholz; Karsten B Sieber; Alexander Teumer; Adrienne Tin; Judy Wang; Bamidele O Tayo; Tarunveer S Ahluwalia; Peter Almgren; Stephan J L Bakker; Bernhard Banas; Nisha Bansal; Mary L Biggs; Eric Boerwinkle; Erwin P Bottinger; Hermann Brenner; Robert J Carroll; John Chalmers; Miao-Li Chee; Miao-Ling Chee; Ching-Yu Cheng; Josef Coresh; Martin H de Borst; Frauke Degenhardt; Kai-Uwe Eckardt; Karlhans Endlich; Andre Franke; Sandra Freitag-Wolf; Piyush Gampawar; Ron T Gansevoort; Mohsen Ghanbari; Christian Gieger; Pavel Hamet; Kevin Ho; Edith Hofer; Bernd Holleczek; Valencia Hui Xian Foo; Nina Hutri-Kähönen; Shih-Jen Hwang; M Arfan Ikram; Navya Shilpa Josyula; Mika Kähönen; Chiea-Chuen Khor; Wolfgang Koenig; Holly Kramer; Bernhard K Krämer; Brigitte Kühnel; Leslie A Lange; Terho Lehtimäki; Wolfgang Lieb; Ruth J F Loos; Mary Ann Lukas; Leo-Pekka Lyytikäinen; Christa Meisinger; Thomas Meitinger; Olle Melander; Yuri Milaneschi; Pashupati P Mishra; Nina Mononen; Josyf C Mychaleckyj; Girish N Nadkarni; Matthias Nauck; Kjell Nikus; Boting Ning; Ilja M Nolte; Michelle L O'Donoghue; Marju Orho-Melander; Sarah A Pendergrass; Brenda W J H Penninx; Michael H Preuss; Bruce M Psaty; Laura M Raffield; Olli T Raitakari; Rainer Rettig; Myriam Rheinberger; Kenneth M Rice; Alexander R Rosenkranz; Peter Rossing; Jerome I Rotter; Charumathi Sabanayagam; Helena Schmidt; Reinhold Schmidt; Ben Schöttker; Christina-Alexandra Schulz; Sanaz Sedaghat; Christian M Shaffer; Konstantin Strauch; Silke Szymczak; Kent D Taylor; Johanne Tremblay; Layal Chaker; Pim van der Harst; Peter J van der Most; Niek Verweij; Uwe Völker; Melanie Waldenberger; Lars Wallentin; Dawn M Waterworth; Harvey D White; James G Wilson; Tien-Yin Wong; Mark Woodward; Qiong Yang; Masayuki Yasuda; Laura M Yerges-Armstrong; Yan Zhang; Harold Snieder; Christoph Wanner; Carsten A Böger; Anna Köttgen; Florian Kronenberg; Cristian Pattaro; Iris M Heid
Journal:  Kidney Int       Date:  2020-10-31       Impact factor: 18.998

2.  Treatment Costs for Patients with Chronic Kidney Disease Who Received Multidisciplinary Care in a District Hospital in Thailand.

Authors:  Suwaporn Songsermlosakul; Unchalee Permsuwan; Wanchana Singhan
Journal:  Clinicoecon Outcomes Res       Date:  2020-04-28

Review 3.  Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.

Authors:  Jan T Kielstein; Roberto Pontremoli; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2020-10-31       Impact factor: 5.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.